Hypermethylation of the Bmp4 promoter dampens binding of HIF-1α and impairs its cardiac protective effects from oxidative stress in prenatally GC-exposed offspring.
Ling-Tong GaoJian-Qiang YuanZhi-Yu ZhangHou-Ming ZhaoLu GaoPublished in: Cellular and molecular life sciences : CMLS (2023)
The exposure to an unhealthy environment in utero can lead to the occurrence of cardiovascular diseases in the offspring. Glucocorticoids (GC) are essential for normal development and maturation of fetal organs and is a first-line treatment for pregnant women affected by autoimmune diseases. However, excess prenatal GC exposure might program the development of fetal organs and cause a number of chronic diseases in later life. Our previous studies indicated that cardiac functions were significantly compromised in rat offspring prenatally exposed to the synthetic glucocorticoid dexamethasone (DEX), only after ischemia-reperfusion. In the present study, we further observed that DNA hypermethylation of bone morphogenetic protein 4 (Bmp4) promoter in cardiomyocytes caused by prenatal DEX exposure substantially dampened the binding activity of transcription factor HIF-1α induced by cardiac ischemia. Therefore, prenatal DEX exposure inhibits the induction of BMP4 upon I/R and attenuates the protective effects of BMP4 in cardiomyocytes, which eventually manifests as malfunction of the adult heart. Moreover, we employed two cardiac-specific Bmp4 knock-in mouse models and found that in vivo BMP4 overexpression could rescue the cardiac dysfunction caused by prenatal GC exposure. In depth mechanistic research revealed that BMP4 protects the cardiomyocytes from mitophagy and apoptosis by attenuating mitochondrial PGC-1α expression in a p-Smad and Parkin-dependent manner. These findings suggest that prenatal GC exposure increases the susceptibility of the offspring's heart to a "second strike" after birth, due to the failure of hypoxia-induced HIF-1α transactivation of the hypermethylated Bmp4 promoter in cardiomyocytes. Pretreatment with the DNA methylation inhibitor, 5-Aza-2'-deoxycytidine, could be a potential therapeutic method for this programming effect of GC exposure during pregnancy on neonatal cardiac dysfunction.
Keyphrases
- pregnant women
- oxidative stress
- mesenchymal stem cells
- dna methylation
- transcription factor
- bone regeneration
- left ventricular
- gene expression
- heart failure
- poor prognosis
- endothelial cells
- risk assessment
- type diabetes
- signaling pathway
- dna binding
- metabolic syndrome
- mouse model
- mass spectrometry
- genome wide
- skeletal muscle
- high glucose
- bone marrow
- epithelial mesenchymal transition
- high dose
- quality improvement
- ischemia reperfusion injury
- single cell
- young adults
- pregnancy outcomes
- pi k akt
- endoplasmic reticulum stress
- adipose tissue
- long non coding rna
- transforming growth factor
- circulating tumor
- cell cycle arrest
- optical coherence tomography